Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

This is a first in human study of NYX-2925. This is a randomized, double-blind,
sponsor-open, placebo-controlled, single and multiple ascending dose, parallel safety,
tolerability, and PK study of oral NYX-2925 in healthy volunteers. The single ascending dose
phase will comprise up to five dose groups. There will be up to 3 dose groups in the
multiple ascending dose phase. One open-label dose group will be repeated in the multiple
ascending dose phase to collect cerebrospinal fluid (CSF) samples, in order to explore
central nervous system penetration. One elderly cohort (single dose) will be completed after
all single and multiple dose escalation groups have completed. One open-label dose group
will be repeated in the single ascending dose phase to collect CSF samples, in order to
establish a more complete cerebral spinal fluid pharmacokinetic profile.

The influence of food ("food effect") on the bioavailability and pharmacokinetics of
NYX-2925 will be explored in one dose group in the single ascending dose phase.

A data review committee will review safety and tolerability (adverse events and other
relevant data), plus preliminary pharmacokinetic data, prior to proceeding to the next
higher dose group, cohort, and/or phase of the study, as well as administration of the fed
dose in the food effect group.

Stopping rules for individual study participants and dose groups or cohorts are established
in order to evaluate the dose escalation scheme, the need to stop or terminate dosing, or to
establish the maximum tolerated dose. If a cohort is stopped due to safety or tolerability
concerns, the previous cohort may be repeated to determine the highest tolerated dose.

Inclusion Criteria:

1. Male and female subjects.

2. 18 to 55 years of age, inclusive, at the time of signing the informed consent form
(ICF). 55 to 80 years of age for elderly cohort.

3. Female subjects with a negative serum pregnancy test prior to entry into the study
and who are practicing an adequate method of birth control (e.g., oral or parenteral
contraceptives, intrauterine device, barrier, abstinence) and who do not plan to
become pregnant during the course of the study.

4. Male subjects and their female sexual partner should use an acceptable method of
birth control during the study. Male subjects must agree to use barrier contraception
(condom with spermicide), and refrain from sperm donation, from the first dose of
study drug until 90 days after the last dose of study drug.

5. Clinical laboratory values within normal limits or deemed not clinically significant
by the investigator and/or the sponsor.

6. Ability to understand the requirements of the study, provide written informed
consent, abide by the study restrictions, and agree to return for the required
assessments.

7. Subject is judged to be in good health as determined by the investigator based on the
results of a medical history, physical examination (PE), clinical laboratory profile,
and electrocardiogram (ECG) performed during the screening period and confirmed prior
to dosing.

8. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive).

9. Normal renal and hepatic function, with calculated creatinine clearance ≥ 90
mL/minute (Cockcroft-Gault Formula) at Screening or ≥ 60 mL/minute only in the case
of the elderly cohort.

Exclusion Criteria:

1. Clinically significant alcohol or other substance abuse within the last 24 months, in
the opinion of the investigator; or, unable to abstain from alcoholic beverages
during the course of the study.

2. Positive screen for alcohol or drugs of abuse (with the exception of a positive
result considered by the investigator to be directly attributable to prescription
medication approved for subject use): including benzodiazepines, opiates, cocaine,
cannabinoids, and amphetamines.

3. History of smoking or tobacco use within 30 days of Screening.

4. Women who are pregnant, breast feeding, or planning to become pregnant during the
course of the study.

5. History of allergy, sensitivity, or intolerance to NMDAR ligands including ketamine,
dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone, as well
as current use of such agents.

6. Received an investigational drug or device within 30 days (or 5 half-lives, whichever
is longer) of dosing.

7. Previously assigned to treatment during this study (except those who did not take
study medication).

8. Screening QT interval corrected for heart rate by Fridericia's formula (QTcF) > 450
(males) or 470 (females) millisecond (msec) or an ECG that is not suitable for QT
measurements (e.g., poorly defined termination of T-wave in the investigator's
opinion).

9. Type I or Type II diabetes.

10. History of severe renal or hepatic impairment, in the opinion of the investigator or
the sponsor-designated medical monitor.

11. History of excessive bleeding, blood thinners within 6 months, antibiotics or
infection within 3 months (CSF cohort only), lumbar spine abnormality, history of
elevated intracranial pressure, normal pressure hydrocephalus or other neurological
conditions considered clinically significant by the investigator.

12. Human immunodeficiency virus infection, hepatitis, or other ongoing infectious
disease that the investigator considers clinically significant.

13. Current evidence of dysplasia or history of malignancy (including lymphoma and
leukemia) in the last 5 years, with the exception of successfully treated
non-metastatic basal cell or squamous cell carcinoma of the skin or localized
carcinoma in situ of the cervix.

14. History of seizures.

15. History of gastrointestinal disease or surgery (except simple appendectomy or hernia
repair), which can influence the absorption of the study drug.

16. History of any type of psychosis (including but not limited to bipolar disease or
schizophrenia).

17. Medical history or conditions that, in the opinion of the investigator, would
preclude safe study participation, or interfere with study procedures/assessments.

18. Evidence of an infection at the time of clinic admission, in the opinion of the
investigator.

19. Poor venous access.

20. Use of prescription or over-the-counter medications, including herbal therapies
within 7 days prior to dosing, or during the treatment and follow-up periods. Use of
St. John's wort within 14 days prior to dosing, or during the treatment and follow-up
periods. Occasional aspirin may be used at the investigator's discretion.

21. Unable to eat a standardized meal offered by the study center.

22. Donated or had a loss of blood or plasma within 8 weeks prior to dosing.

23. Grapefruit juice or Seville oranges within 14 days prior to dosing or during the
dosing period.

24. Heart rate ≤ 45 beats per minutes.